Dr. Lucas Chan is the Chief Scientific Officer of CellVec in Singapore, a CDMO dedicated to the development and manufacture of viral vectors for human gene therapy. Lucas received his PhD at Imperial College London and was a Senior Investigator and Head of Manufacture for Advanced Therapies at King’s Health Partners in London, where he led the translational development of ATMPs for the clinic and established UK’s first GMP viral vector core. He is an elected Fellow of the Royal Society of Biology and an advisory member to Singapore’s Ministry of Health on cell and gene therapy regulations.